Tumor detection by analysis of both symmetric- and hemi-methylation of plasma cell-free DNA.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 39030196.
- Also identified by DOI 10.1038/s41467-024-50471-1 and PMC identifier 11271492.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Aberrant DNA methylation patterns have been used for cancer detection. However, DNA hemi-methylation, present at about 10% CpG dinucleotides, has been less well studied. Here we show that a majority of differentially hemi-methylated regions (DHMRs) in liver tumor DNA or plasma cells free (cf) DNA do not overlap with differentially methylated regions (DMRs) of the same samples, indicating that DHMRs could serve as independent biomarkers. Furthermore, we analyzed the cfDNA methylomes of 215 samples from individuals with liver or brain cancer and individuals without cancer (controls), and trained machine learning models using DMRs, DHMRs or both. The models incorporated with both DMRs and DHMRs show a superior performance compared to models trained with DMRs or DHMRs, with AUROC being 0.978, 0.990, and 0.983 in distinguishing control, liver and brain cancer, respectively, in a validation cohort. This study supports the potential of utilizing both DMRs and DHMRs for multi-cancer detection.
Medical subject headings
- DNA Methylation
- Brain Neoplasms
- Cell-Free Nucleic Acids
- Liver Neoplasms
- Biomarkers, Tumor